Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In PARP inhibitor-resistant A172 glioblastoma cells, our PARG inhibitor shows comparable killing to Nedaplatin, providing further proof-of-concept that selectively inhibiting PARG can impair cancer cell survival.
|
31827085 |
2019 |
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Myc targeted CDK18 promotes ATR and homologous recombination to mediate PARP inhibitor resistance in glioblastoma.
|
31266951 |
2019 |
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, our results revealed the ability of luteolin to induce caspase and PARP cleavages in glioblastoma cells in addition to promoting cell cycle arrest.
|
29935053 |
2018 |
Adult Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Moreover, NK-EM cytotoxicity for glioblastoma cells that related with decreased levels of the cell survival markers p-ERK and p-AKT, and increased levels of apoptosis protein markers cleaved-caspase 3, cytochrome-c and cleaved-PARP was confirmed.
|
30092165 |
2018 |
Adult Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Glioblastoma xenograft tumors treated with VB showed elevated SHP-1, Bax, cleaved caspase-3, and cleaved PARP expression and reduced p-STAT3, Bcl-2, survivin, MMP-2, and MMP-9 expression. siRNA-SHP-1 inhibited the VB effects on glioblastoma.
|
29961065 |
2018 |
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
PARP Inhibitors for Sensitization of Alkylation Chemotherapy in Glioblastoma: Impact of Blood-Brain Barrier and Molecular Heterogeneity.
|
30723695 |
2018 |
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, PARP inhibitor combined with DNA damage inducing agents can be utilized in patients with glioblastoma displaying defects in D-NHEJ.
|
30627327 |
2018 |
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A potential clinical scenario, intratumoral convection-enhanced delivery, was mimicked using an orthotopic glioblastoma model combined with an implanted osmotic pump system to study local administration of <sup>131</sup>I-PARPi (PARPi is PARP inhibitor).
|
29572254 |
2018 |
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Combining PARP inhibitors with radiation therapy for the treatment of glioblastoma: Is PTEN predictive of response?
|
27655368 |
2017 |
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Enhanced efficacy of combined HDAC and PARP targeting in glioblastoma.
|
26794465 |
2016 |
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System.
|
26438157 |
2015 |
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
PARP inhibition restores extrinsic apoptotic sensitivity in glioblastoma.
|
25531448 |
2014 |
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
ABT-888 is a PARP inhibitor undergoing extensive clinical evaluation in glioblastoma, because it may synergize with the standard-of-care temozolomide (TMZ).
|
24647572 |
2014 |